Annemieke M. Boot
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Annemieke M. Boot has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Conny van Wijngaard-De Vugt
WV Research, Advice and Management, Brunssum, The Netherlands
4 shared publications - Evangelia Kalaitzoglou
Department of Pediatrics, University of Kentucky, Barnstable Brown Diabetes Center, Lexington, KY, United States
4 shared publications - Stenvert L. S. Drop
Division of Endocrinology, Department of Pediatrics, Sophia Children's Hospital, Erasmus MC, Rotterdam, The Netherlands
4 shared publications - M. Carola Zillikens
Erasmus MC Bone Center, Department of Internal Medicine, Erasmus University Medical Center, Rotterdam, the Netherlands
3 shared publications - Maria Luisa Brandi
Institute of Endocrine and Metabolic Sciences, Vita-Salute San Raffaele University and IRCCS , 20132 Milan
3 shared publications Vera van Tellingen
Division of Pediatric Endocrinology, Department of Pediatrics, Catharina Hospital, Eindhoven, The Netherlands
3 shared publications
Latest Publications
- Open Access
- 23 June 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (1) , 10-21
Second interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia
Objective: X-linked hypophosphataemia (XLH) is a rare genetic disorder characterised by defective bone and tooth mineralisation. Burosumab is a recombinant, human, anti-fibroblast growth factor 23 monoclonal antibody approved for treating XLH. Due to the rarity of the disease, additional safety data for the treatment of XLH with burosumab are required. Design: A post-authorisation safety study analysis of data for paediatric participants from the International X-linked Hypophosphataemia Registry. This study included standard diagnostic and monitoring clinical data at participating centres, regardless of treatment. Methods: This was a second interim analysis performed 5 years after study initiation in the paediatric population. Primary objectives assessed safety outcomes in children and adolescents with XLH. The secondary objective compared safety outcomes with burosumab vs phosphate and/or active vitamin D. Results: In total, 340 participants were treated with ≥1 dose of burosumab, and 91 were treated with phosphate and/or active vitamin D. Overall, 37.4% and 22.0% of participants in the burosumab or phosphate and/or active vitamin D cohorts, respectively, experienced ≥1 adverse event. The proportions of participants with events were similar among children and adolescents. Forty-nine (14.4%) participants reported events possibly/probably related to burosumab. No events led to the withdrawal of burosumab. In both cohorts, no serious adverse events were considered related to treatment, and there were no deaths. Hospitalisations occurred in ∼71% of participants. Hyperphosphataemia, elevated parathyroid hormone, and ectopic mineralisation events were rare. Conclusions: The safety profile of burosumab was consistent with previous studies, and no new safety concerns were reported for children or adolescents.
- 23 June 2026
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 195 (1) , 10-21
Open AccessSecond interim analysis of the post-authorisation safety study (PASS) of burosumab in paediatric patients with X-linked hypophosphataemia
Objective: X-linked hypophosphataemia (XLH) is a rare genetic disorder characterised by defective bone and tooth mineralisation. Burosumab is a recombinant, human, anti-fibroblast growth factor 23 monoclonal antibody approved for treating XLH. Due to the rarity of the disease, additional safety data for the treatment of XLH with burosumab are required. Design: A post-authorisation safety study analysis of data for paediatric participants from the International X-linked Hypophosphataemia Registry. This study included standard diagnostic and monitoring clinical data at participating centres, regardless of treatment. Methods: This was a second interim analysis performed 5 years after study initiation in the paediatric population. Primary objectives assessed safety outcomes in children and adolescents with XLH. The secondary objective compared safety outcomes with burosumab vs phosphate and/or active vitamin D. Results: In total, 340 participants were treated with ≥1 dose of burosumab, and 91 were treated with phosphate and/or active vitamin D. Overall, 37.4% and 22.0% of participants in the burosumab or phosphate and/or active vitamin D cohorts, respectively, experienced ≥1 adverse event. The proportions of participants with events were similar among children and adolescents. Forty-nine (14.4%) participants reported events possibly/probably related to burosumab. No events led to the withdrawal of burosumab. In both cohorts, no serious adverse events were considered related to treatment, and there were no deaths. Hospitalisations occurred in ∼71% of participants. Hyperphosphataemia, elevated parathyroid hormone, and ectopic mineralisation events were rare. Conclusions: The safety profile of burosumab was consistent with previous studies, and no new safety concerns were reported for children or adolescents.
- Open Access
- 20 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344902
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis
X-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations. Burosumab is a fully human monoclonal antibody that targets circulating fibroblast growth factor 23 and directly inhibits its activity, thereby correcting the abnormal phosphate homoeostasis in people with X-linked hypophosphataemia (XLH). The efficacy and safety of burosumab has been demonstrated in a programme of clinical trials in children and adults. Few data describe the experience of adolescents with XLH receiving burosumab treatment before and after skeletal growth ends. This prospective, multicentre, mixed-methods study described the lived experience of adolescents with XLH treated with burosumab at the end of skeletal growth (NCT05181839). Using patient-reported outcomes, wearable devices, and interviews, we found low median symptom severity scores for pain (0.00), stiffness (0.00), and fatigue (1.75) on a 0–10 scale. Symptoms were usually triggered by physical activity but rarely interfered with daily life. Some adolescents reported emotional concerns related to XLH and treatment transition. These insights can inform patient support during transition to adult care.
- 20 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344902
Open AccessThe lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysis
X-linked hypophosphataemia is a rare, genetic, lifelong disorder caused by phosphate-regulating endopeptidase homologue X-linked pathogenic variants and, if left untreated, is associated with a progressive accumulation of musculoskeletal manifestations. Burosumab is a fully human monoclonal antibody that targets circulating fibroblast growth factor 23 and directly inhibits its activity, thereby correcting the abnormal phosphate homoeostasis in people with X-linked hypophosphataemia (XLH). The efficacy and safety of burosumab has been demonstrated in a programme of clinical trials in children and adults. Few data describe the experience of adolescents with XLH receiving burosumab treatment before and after skeletal growth ends. This prospective, multicentre, mixed-methods study described the lived experience of adolescents with XLH treated with burosumab at the end of skeletal growth (NCT05181839). Using patient-reported outcomes, wearable devices, and interviews, we found low median symptom severity scores for pain (0.00), stiffness (0.00), and fatigue (1.75) on a 0–10 scale. Symptoms were usually triggered by physical activity but rarely interfered with daily life. Some adolescents reported emotional concerns related to XLH and treatment transition. These insights can inform patient support during transition to adult care.
- Open Access
- 30 January 2026
- Published by JMIR Publications Inc. in JMIR Medical Education
- Vol. 12 (1) , e67332
Global Learner Feedback on Continuing Medical Education–Accredited e-Learning Modules in Pediatric Endocrinology and Diabetes: Cross-Sectional Study
Background: The European Society for Paediatric Endocrinology (ESPE) e-Learning wesite is a free, globally accessible online resource to enhance learning in pediatric endocrinology and pediatric diabetes. The content is created by world-leading experts in pediatric endocrinology and pediatric diabetes and is closely aligned with published international consensus guidelines. In August 2022, 30 hours of e-learning courses received accreditation from the European Accreditation Council for Continuing Medical Education (CME). These CME courses cover three categories: (1) pediatric endocrinology, (2) pediatric diabetes, and (3) pediatric endocrinology in resource-limited settings. Objective: This study aimed to assess learners’ demographics and feedback from mandatory surveys after completion of CME e-learning courses and to identify areas for improvement. Methods: The ESPE e-learning committee created a mandatory survey for each CME e-learning module. The survey includes baseline demographics and feedback on the quality of the learning content, assessed using a 5-point Likert scale. Data were extracted from the start of the CME modules in August 2022 until September 2025. Results: A total of 567 surveys were completed: 286 (50.4%) in the category pediatric endocrinology, 225 (39.7%) in the category pediatric diabetes based on the International Society for Pediatric and Adolescent Diabetes guidelines, and 56 (9.9%) in the category pediatric endocrinology in resource-limited settings. There was global participation, with most learners practicing in Europe (n=333, 59%), followed by Asia (n=124, 22%), Africa (n=53, 9%), the Americas (North America, n=45, 8%; and South America, n=11, 2%), and Oceania (n=1, 0%). Most of the users indicated that they were medical experts (n=210, 37%), followed by fellows or residents (n=223, 39%), and medical students and nurses (n=29, 5% and n=32, 6%, respectively); overall, 10% (n=56) of learners practice in resource-limited countries. Overall, the learning content was well received for all modules regarding accessibility, organization, level of interest, improvement of learners’ clinical practice, appropriateness of content, and provision of feedback (median Likert score 4, IQR 4-5). Learners’ free-text feedback identified some areas for improvement, including reducing text-heavy content and providing more graphical content and more interactive case reports. Most learners’ free-text feedback consisted of encouraging and thankful comments. Conclusions: The ESPE CME–accredited e-learning modules are well received, providing globally free CME education in pediatric endocrinology and pediatric diabetes. These findings support the continued development and promotion of open-access CME platforms, with the aim of improving global equity in specialist medical education and focusing on educational impact.
- 30 January 2026
- Published by JMIR Publications Inc. in JMIR Medical Education
- Vol. 12 (1) , e67332
Open AccessGlobal Learner Feedback on Continuing Medical Education–Accredited e-Learning Modules in Pediatric Endocrinology and Diabetes: Cross-Sectional Study
Background: The European Society for Paediatric Endocrinology (ESPE) e-Learning wesite is a free, globally accessible online resource to enhance learning in pediatric endocrinology and pediatric diabetes. The content is created by world-leading experts in pediatric endocrinology and pediatric diabetes and is closely aligned with published international consensus guidelines. In August 2022, 30 hours of e-learning courses received accreditation from the European Accreditation Council for Continuing Medical Education (CME). These CME courses cover three categories: (1) pediatric endocrinology, (2) pediatric diabetes, and (3) pediatric endocrinology in resource-limited settings. Objective: This study aimed to assess learners’ demographics and feedback from mandatory surveys after completion of CME e-learning courses and to identify areas for improvement. Methods: The ESPE e-learning committee created a mandatory survey for each CME e-learning module. The survey includes baseline demographics and feedback on the quality of the learning content, assessed using a 5-point Likert scale. Data were extracted from the start of the CME modules in August 2022 until September 2025. Results: A total of 567 surveys were completed: 286 (50.4%) in the category pediatric endocrinology, 225 (39.7%) in the category pediatric diabetes based on the International Society for Pediatric and Adolescent Diabetes guidelines, and 56 (9.9%) in the category pediatric endocrinology in resource-limited settings. There was global participation, with most learners practicing in Europe (n=333, 59%), followed by Asia (n=124, 22%), Africa (n=53, 9%), the Americas (North America, n=45, 8%; and South America, n=11, 2%), and Oceania (n=1, 0%). Most of the users indicated that they were medical experts (n=210, 37%), followed by fellows or residents (n=223, 39%), and medical students and nurses (n=29, 5% and n=32, 6%, respectively); overall, 10% (n=56) of learners practice in resource-limited countries. Overall, the learning content was well received for all modules regarding accessibility, organization, level of interest, improvement of learners’ clinical practice, appropriateness of content, and provision of feedback (median Likert score 4, IQR 4-5). Learners’ free-text feedback identified some areas for improvement, including reducing text-heavy content and providing more graphical content and more interactive case reports. Most learners’ free-text feedback consisted of encouraging and thankful comments. Conclusions: The ESPE CME–accredited e-learning modules are well received, providing globally free CME education in pediatric endocrinology and pediatric diabetes. These findings support the continued development and promotion of open-access CME platforms, with the aim of improving global equity in specialist medical education and focusing on educational impact.
- Open Access
- 26 January 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (2)
HRQoL in adolescents with idiopathic isolated GHD: rhGH (dis)continuation in mid-puberty
Objective: To evaluate health-related quality of life (HRQoL) in adolescents with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH-sufficient, comparing those who discontinued recombinant human growth hormone (rhGH) at mid-puberty with those who continued until near-adult height (NAH). Design: This multicentre prospective study used a patient-preference design. Previous findings showed that NAH did not differ between groups. Height influences quality of life (QoL), particularly during adolescence when appearance and social comparison affect psychological development. The impact of height and treatment decisions on HRQoL during puberty remains unclear. Methods: Adolescents with IIGHD who had received rhGH for ≥3 years and tested GH-sufficient in mid-puberty chose to continue or discontinue treatment. HRQoL was assessed at mid-puberty and NAH using QoLISSY (patient and parent reports), supplemented by KIDSCREEN-52, SDQ, and EQ-5D-Y. Results: Of 127 participants, 44 continued rhGH and 83 discontinued. Questionnaire completion was 58% (n = 74) at mid-puberty and 66% (n = 84) at NAH. No significant differences in patient-reported QoL were observed between groups at either time point. Parents reported higher QoL in the discontinuation group at mid-puberty. Overall, QoL scores were within normal ranges and positively correlated with height SDS at both time points. Conclusions: Discontinuing rhGH in adolescents with IIGHD who tested GH-sufficient at mid-puberty does not appear to negatively affect perceived QoL. Parental reports suggest greater well-being in the discontinuation group, possibly reflecting pre-existing satisfaction with height and health. These findings emphasize considering both physical and psychosocial factors in treatment decisions and incorporating patient and parent perspectives during puberty.
- 26 January 2026
- Published by Bioscientifica in Endocrine Connections
- Vol. 15 (2)
Open AccessHRQoL in adolescents with idiopathic isolated GHD: rhGH (dis)continuation in mid-puberty
Objective: To evaluate health-related quality of life (HRQoL) in adolescents with idiopathic isolated growth hormone deficiency (IIGHD) who tested GH-sufficient, comparing those who discontinued recombinant human growth hormone (rhGH) at mid-puberty with those who continued until near-adult height (NAH). Design: This multicentre prospective study used a patient-preference design. Previous findings showed that NAH did not differ between groups. Height influences quality of life (QoL), particularly during adolescence when appearance and social comparison affect psychological development. The impact of height and treatment decisions on HRQoL during puberty remains unclear. Methods: Adolescents with IIGHD who had received rhGH for ≥3 years and tested GH-sufficient in mid-puberty chose to continue or discontinue treatment. HRQoL was assessed at mid-puberty and NAH using QoLISSY (patient and parent reports), supplemented by KIDSCREEN-52, SDQ, and EQ-5D-Y. Results: Of 127 participants, 44 continued rhGH and 83 discontinued. Questionnaire completion was 58% (n = 74) at mid-puberty and 66% (n = 84) at NAH. No significant differences in patient-reported QoL were observed between groups at either time point. Parents reported higher QoL in the discontinuation group at mid-puberty. Overall, QoL scores were within normal ranges and positively correlated with height SDS at both time points. Conclusions: Discontinuing rhGH in adolescents with IIGHD who tested GH-sufficient at mid-puberty does not appear to negatively affect perceived QoL. Parental reports suggest greater well-being in the discontinuation group, possibly reflecting pre-existing satisfaction with height and health. These findings emphasize considering both physical and psychosocial factors in treatment decisions and incorporating patient and parent perspectives during puberty.
- Open Access
- 8 December 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
Plain language summary of the first findings from the International X-Linked Hypophosphatemia (XLH) Registry
- 8 December 2025
- Published by Taylor & Francis in Future Rare Diseases
- Vol. 5 (1)
Open AccessPlain language summary of the first findings from the International X-Linked Hypophosphatemia (XLH) Registry
- Open Access
- 15 November 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1319-1328
Growth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD
Context: In children with idiopathic isolated growth hormone deficiency (IIGHD), GH secretion often normalizes by near adult height (NAH). Whether recombinant human GH (rhGH) treatment can be safely discontinued earlier remains unclear. Objective: This work aimed to investigate if withdrawing rhGH treatment from mid-puberty onward had no negative effect on attained NAH in adolescents who, after retesting, were no longer GH deficient. Methods: A prospective multicenter patient preference study was conducted at pediatric endocrinology departments in multiple centers (2017-2024) with follow-up until NAH (SEENEZ GH Study). Participants included 127 adolescents (95 male, 75%) with childhood IIGHD (GH peak 1.7-10 µg/L) who tested GH sufficient (GH peak >6.7 µg/L) at mid-puberty. Forty-four continued rhGH (GHcont), 83 discontinued (GHstop). A total of 99% of patients completed the study. Intervention included rhGH treatment continuation vs discontinuation from mid-puberty until NAH. The primary outcome measure was NAH-SDS minus target height (TH)-SDS. The secondary outcome was NAH-SDS, total pubertal growth (TPG), and predicted vs attained height gain. Results: Mean (SD) NAH-SDS minus TH-SDS was −0.17 (0.60) in the GHcont and −0.18 (0.62) in the GHstop group (P = .96). Mean NAH-SDS was −0.91 (0.76) (GHcont) vs −0.78 (0.76) (GHstop) (P = .35). Mean (SD) TPG (from start of puberty) in males was 27.5 cm (7.0; GHcont) vs 25.9 cm (6.2; GHstop) (P = .25) and in females 20.5 cm (5.7; GHcont) vs 20.9 cm (7.6; GHstop) (P = .90). Predicted vs attained height gain based on the prediction model did not differ between groups. Conclusions: In adolescents with transient IIGHD, rhGH treatment can be stopped at mid-puberty. These findings support reducing rhGH treatment duration, lowering patient burden and health-care costs.
- 15 November 2025
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (5) , 1319-1328
Open AccessGrowth Hormone Withdrawal in Mid-Puberty: No Impact on Near Adult Height in Adolescents With Transient Idiopathic GHD
Context: In children with idiopathic isolated growth hormone deficiency (IIGHD), GH secretion often normalizes by near adult height (NAH). Whether recombinant human GH (rhGH) treatment can be safely discontinued earlier remains unclear. Objective: This work aimed to investigate if withdrawing rhGH treatment from mid-puberty onward had no negative effect on attained NAH in adolescents who, after retesting, were no longer GH deficient. Methods: A prospective multicenter patient preference study was conducted at pediatric endocrinology departments in multiple centers (2017-2024) with follow-up until NAH (SEENEZ GH Study). Participants included 127 adolescents (95 male, 75%) with childhood IIGHD (GH peak 1.7-10 µg/L) who tested GH sufficient (GH peak >6.7 µg/L) at mid-puberty. Forty-four continued rhGH (GHcont), 83 discontinued (GHstop). A total of 99% of patients completed the study. Intervention included rhGH treatment continuation vs discontinuation from mid-puberty until NAH. The primary outcome measure was NAH-SDS minus target height (TH)-SDS. The secondary outcome was NAH-SDS, total pubertal growth (TPG), and predicted vs attained height gain. Results: Mean (SD) NAH-SDS minus TH-SDS was −0.17 (0.60) in the GHcont and −0.18 (0.62) in the GHstop group (P = .96). Mean NAH-SDS was −0.91 (0.76) (GHcont) vs −0.78 (0.76) (GHstop) (P = .35). Mean (SD) TPG (from start of puberty) in males was 27.5 cm (7.0; GHcont) vs 25.9 cm (6.2; GHstop) (P = .25) and in females 20.5 cm (5.7; GHcont) vs 20.9 cm (7.6; GHstop) (P = .90). Predicted vs attained height gain based on the prediction model did not differ between groups. Conclusions: In adolescents with transient IIGHD, rhGH treatment can be stopped at mid-puberty. These findings support reducing rhGH treatment duration, lowering patient burden and health-care costs.
- Open Access
- 12 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Learner’s feedback on the use of free, globally accessible CME-accredited e-learning modules in Paediatric Endocrinology and Diabetes (Preprint)
BACKGROUND The European Society for Paediatric Endocrinology (ESPE) e-Learning website, www.espe-elearning.org, is a free, globally accessible online resource to enhance learning in Paediatric Endocrinology and Diabetes. The content is created by world-leading experts in Paediatric Endocrinology and Diabetes and is closely aligned with published international consensus guidelines. In August 2022, 30 hours of e-learning courses received accreditation from the European Accreditation Council for CME (EACCME®). These CME courses cover three categories: (1) Paediatric Endocrinology, (2) Paediatric Diabetes, and (3) Paediatric Endocrinology in Resource Limited Setting. OBJECTIVE To assess learners' demographics and feedback from mandatory surveys after completion of CME e-learning courses, and identify areas for improvement METHODS The ESPE e-learning committee created a mandatory survey for each CME e-learning module. The survey includes baseline demographics and feedback on the quality of the learning content, assessed using a five-level Likert scale. Data was extracted from the start of the CME modules in August 2022 until April 2024. RESULTS From August 2022 until April 2024, 324 surveys were completed: 144 (44%) in the category Paediatric Endocrinology, 140 (43%) in the category Paediatric Diabetes ISPAD Guidelines, and 40 (12%) in the category Paediatric Endocrinology in Resource Limited Setting. There was global participation, with most learners practising in Europe (n=202 (62%)), followed by the Americas (n=36 [11 %] North America, n=11 [3%] South America), Asia (n= 45 [14%]), Africa (n=29 [9%]), and Oceania (n=1 [0.31%]). Most of the users indicated to be medical experts (37%), followed by fellows/residents (33%), medical students and nurses (7% and 8%, respectively); 9% of learners practise in resource-limited countries. Overall, the learning content was well received for all modules regarding accessibility, organisation, level of interest, improvement of learner’s clinical practice, appropriateness of content and provision of feedback (Likert scale 1-2/5). Learners’ free-text feedback identified some areas of improvement, including reducing text-heavy content, providing more graphical content and more interactive case reports. Most learners' free text feedback consists of encouraging and thankful comments. CONCLUSIONS The ESPE CME-accredited e-learning modules are well-received and accessed globally to provide free CME education in Paediatric Endocrinology and Diabetes.
- 12 October 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessLearner’s feedback on the use of free, globally accessible CME-accredited e-learning modules in Paediatric Endocrinology and Diabetes (Preprint)
BACKGROUND The European Society for Paediatric Endocrinology (ESPE) e-Learning website, www.espe-elearning.org, is a free, globally accessible online resource to enhance learning in Paediatric Endocrinology and Diabetes. The content is created by world-leading experts in Paediatric Endocrinology and Diabetes and is closely aligned with published international consensus guidelines. In August 2022, 30 hours of e-learning courses received accreditation from the European Accreditation Council for CME (EACCME®). These CME courses cover three categories: (1) Paediatric Endocrinology, (2) Paediatric Diabetes, and (3) Paediatric Endocrinology in Resource Limited Setting. OBJECTIVE To assess learners' demographics and feedback from mandatory surveys after completion of CME e-learning courses, and identify areas for improvement METHODS The ESPE e-learning committee created a mandatory survey for each CME e-learning module. The survey includes baseline demographics and feedback on the quality of the learning content, assessed using a five-level Likert scale. Data was extracted from the start of the CME modules in August 2022 until April 2024. RESULTS From August 2022 until April 2024, 324 surveys were completed: 144 (44%) in the category Paediatric Endocrinology, 140 (43%) in the category Paediatric Diabetes ISPAD Guidelines, and 40 (12%) in the category Paediatric Endocrinology in Resource Limited Setting. There was global participation, with most learners practising in Europe (n=202 (62%)), followed by the Americas (n=36 [11 %] North America, n=11 [3%] South America), Asia (n= 45 [14%]), Africa (n=29 [9%]), and Oceania (n=1 [0.31%]). Most of the users indicated to be medical experts (37%), followed by fellows/residents (33%), medical students and nurses (7% and 8%, respectively); 9% of learners practise in resource-limited countries. Overall, the learning content was well received for all modules regarding accessibility, organisation, level of interest, improvement of learner’s clinical practice, appropriateness of content and provision of feedback (Likert scale 1-2/5). Learners’ free-text feedback identified some areas of improvement, including reducing text-heavy content, providing more graphical content and more interactive case reports. Most learners' free text feedback consists of encouraging and thankful comments. CONCLUSIONS The ESPE CME-accredited e-learning modules are well-received and accessed globally to provide free CME education in Paediatric Endocrinology and Diabetes.
- Open Access
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 15
Real-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis. Burosumab is a recombinant human monoclonal antibody that inhibits FGF23, restoring patient serum phosphate levels. Safety data on long-term burosumab treatment are currently limited. Objectives: This post-authorization safety study (PASS) aims to monitor long-term safety outcomes in children and adolescents (1–17 years) treated with burosumab for XLH. This first interim analysis reports the initial PASS safety outcomes. Design: A 10-year retrospective and prospective cohort study. Methods: This PASS utilizes International XLH Registry (NCT03193476) data, which includes standard diagnostic and monitoring practice data at participating European centers. Results: At data cut-off (13 May 2021), 647 participants were included in the International XLH Registry; 367 were receiving burosumab, of which 67 provided consent to be included in the PASS. Mean (SD) follow-up time was 2.2 (1.0) years. Mean (SD) age was 7.3 (4.3) years (range 1.0–17.5 years). Mean duration of burosumab exposure was 29.7 (25.0) months. Overall, 25/67 participants (37.3%) experienced ⩾1 adverse event (AE) during follow-up; 83 AEs were reported. There were no deaths, no AEs leading to treatment withdrawal, nor serious AEs related to treatment. The most frequently reported AEs were classified as ‘musculoskeletal and connective tissue disorders’, with ‘pain in extremity’ most frequently reported, followed by ‘infections and infestations’, with ‘tooth abscess’ the most frequently reported. Conclusion: In this first interim analysis of the PASS, covering the initial 2 years of data collection, the safety profile of burosumab is consistent with previously reported safety data. The PASS will provide long-term safety data over its 10-year duration for healthcare providers and participants with XLH that contribute to improvements in the knowledge of burosumab safety. Trial registration: European Union electronic Register of Post-Authorisation Studies: EUPAS32190.
- 1 January 2024
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 15
Open AccessReal-world non-interventional post-authorization safety study of long-term use of burosumab in children and adolescents with X-linked hypophosphatemia: first interim analysis
Background: X-linked hypophosphatemia (XLH) is a rare, progressive disorder characterized by excess fibroblast growth factor 23 (FGF23), causing renal phosphate-wasting and impaired active vitamin D synthesis. Burosumab is a recombinant human monoclonal antibody that inhibits FGF23, restoring patient serum phosphate levels. Safety data on long-term burosumab treatment are currently limited. Objectives: This post-authorization safety study (PASS) aims to monitor long-term safety outcomes in children and adolescents (1–17 years) treated with burosumab for XLH. This first interim analysis reports the initial PASS safety outcomes. Design: A 10-year retrospective and prospective cohort study. Methods: This PASS utilizes International XLH Registry (NCT03193476) data, which includes standard diagnostic and monitoring practice data at participating European centers. Results: At data cut-off (13 May 2021), 647 participants were included in the International XLH Registry; 367 were receiving burosumab, of which 67 provided consent to be included in the PASS. Mean (SD) follow-up time was 2.2 (1.0) years. Mean (SD) age was 7.3 (4.3) years (range 1.0–17.5 years). Mean duration of burosumab exposure was 29.7 (25.0) months. Overall, 25/67 participants (37.3%) experienced ⩾1 adverse event (AE) during follow-up; 83 AEs were reported. There were no deaths, no AEs leading to treatment withdrawal, nor serious AEs related to treatment. The most frequently reported AEs were classified as ‘musculoskeletal and connective tissue disorders’, with ‘pain in extremity’ most frequently reported, followed by ‘infections and infestations’, with ‘tooth abscess’ the most frequently reported. Conclusion: In this first interim analysis of the PASS, covering the initial 2 years of data collection, the safety profile of burosumab is consistent with previously reported safety data. The PASS will provide long-term safety data over its 10-year duration for healthcare providers and participants with XLH that contribute to improvements in the knowledge of burosumab safety. Trial registration: European Union electronic Register of Post-Authorisation Studies: EUPAS32190.
- Open Access
- 15 July 2023
- Published by Elsevier in Bone Reports
- Vol. 19, 101699
A novel mutation in PTHLH in a family with a variable phenotype with brachydactyly, short stature, oligodontia and developmental delay
- 15 July 2023
- Published by Elsevier in Bone Reports
- Vol. 19, 101699
Open AccessA novel mutation in PTHLH in a family with a variable phenotype with brachydactyly, short stature, oligodontia and developmental delay